Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Omeprazole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATP4A known ✓ | P20648 | 6/20 | 0.48 |
| ▸ | ATP4B known ✓ | P51164 | 6/20 | 0.48 |
| ▸ | BRS3 | P32247 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.48 |
| ▸ | ATP1A1 | P05023 | 4/20 | 0.48 |
| ▸ | ATP1B1 | P05026 | 4/20 | 0.48 |
| ▸ | ATP1A3 | P13637 | 4/20 | 0.48 |
| ▸ | ATP1B2 | P14415 | 4/20 | 0.48 |
| ▸ | ATP1A2 | P50993 | 4/20 | 0.48 |
| ▸ | ATP1B3 | P54709 | 4/20 | 0.48 |
| ▸ | FXYD2 | P54710 | 4/20 | 0.48 |
| ▸ | ATP1A4 | Q13733 | 4/20 | 0.48 |
| ▸ | WDR5 | P61964 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.48 |
| ▸ | DDAH1 | O94760 | 2/20 | 0.48 |
| ▸ | ENGASE | Q8NFI3 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Esomeprazole SCHEMBL6864877 | 1.00 | BRS3 (0.50) | BRS3ATP4AATP4BKMT2AATP1A1 | |
| Esomeprazole SCHEMBL29002845 | 1.00 | BRS3 (0.50) | BRS3ATP4AATP4BKMT2AATP1A1 | |
| Omeprazole SCHEMBL6829013 | 1.00 | BRS3 (0.50) | BRS3ATP4AATP4BKMT2AATP1A1 | |
| Omeprazole SCHEMBL142791 | 1.00 | BRS3 (0.50) | BRS3ATP4AATP4BKMT2AATP1A1 | |
| Esomeprazole SCHEMBL142905 | 1.00 | BRS3 (0.50) | BRS3ATP4AATP4BKMT2AATP1A1 | |
| Omeprazole SCHEMBL1713666 | 1.00 | BRS3 (0.50) | BRS3ATP4AATP4BKMT2AATP1A1 | |
| Esomeprazole SCHEMBL2484203 | 1.00 | BRS3 (0.50) | BRS3ATP4AATP4BKMT2AATP1A1 | |
| Esomeprazole SCHEMBL1292977 | 0.99 | BRS3 (0.51) | BRS3ATP4AATP4BKMT2AATP1A1 | |
| Omeprazole SCHEMBL2516725 | 0.99 | BRS3 (0.51) | BRS3ATP4AATP4BKMT2AATP1A1 | |
| Omeprazole SCHEMBL18951954 | 0.99 | BRS3 (0.51) | BRS3ATP4AATP4BKMT2AATP1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023121629-A1 | COMBINATION OF CAMOSTAT MESILAT AND UMIFENOVIR HYDROCHLORIDE WITH PROTON PUMP INHIBITORS | TASKIN TAMBAY (TR) | 2023-06-29 | — | — | WO | disclosed |
| WO-2020040438-A1 | PHARMACEUTICAL PREPARATION HAVING EXCELLENT DISSOLUTION PROPERTIES, CONTAINING ESOMEPRAZOLE AND SODIUM BICARBONATE | 주식회사 종근당 | 2020-02-27 | — | — | WO | disclosed |
| WO-2009074997-A2 | A NOVEL PROCESS FOR THE PREPARATION OF CRYSTALLINE MAGNESIUM SALT OF (S)-OMEPRAZOLE DI HYDRATE | LEE PHARMA LTD. (IN) | 2009-06-18 | — | — | WO | disclosed |
| WO-2007016128-A2 | MAGNESIUM SALT PROTON PUMP INHIBITOR DOSAGE FORMS | QPHARMA, LLC (US) | 2007-02-08 | — | — | WO | disclosed |
| US-20070026071-A1 | Magnesium salt proton pump inhibitor dosage forms | QPHARMA, LLC | 2007-02-01 | — | — | US | disclosed |
| CN-1728997-A | Amorphous salt of (ES) omeprazole | RANBAXY LAB LTD (IN) | 2006-02-01 | — | — | CN | disclosed |
| WO-2004089935-A1 | NOVEL CRYSTALLINE FORMS OF S-OMEPRAZOLE MAGNESIUM | HETERO DRUGS LIMITD (IN) | 2004-10-21 | — | — | WO | disclosed |
| US-6747155-B2 | REACTING POTASSIUM SALT WITH MAGNESIUM COMPOUND | ASTRAZENECA AB (SE) | 2004-06-08 | — | — | US | disclosed |
| US-20030004190-A1 | Process | ASTRAZENECA AB (SE) | 2003-01-02 | — | — | US | disclosed |